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Background. Henoch-Sch¨ onlein purpura (HSP) is the most common childhood vasculitis with an incidence of approximately
10 per 100000 children. There is some evidence to support steroid therapy in the treatment of severe abdominal pain, severe
nephritis, and central nervous system involvement. However, the routine use of corticosteroids is controversial. Frequent relapses,
lackofresponsetosteroid,steroiddependency,andsteroidsideeﬀectsmayoccurinsomepatients.Mycophenolatemofetil(MMF)
gains increasing popularity in the treatment of autoimmune disorders, but hitherto, the available evidence to support the use of
MMF in HSP is limited to some case study reports. Case Presentation. We report six children with HSP who failed to respond to
systemic steroid therapy, whereas MMF successfully treated the manifestations of the disease. Conclusion. The manifestations of
HSP disappeared mainly during the ﬁrst week of treatment with MMF and all the patients were in a complete remission at the
end and after discontinuation of the therapy. In our experience, MMF appeared to be safe and eﬀective for the maintenance of
remission in the HSP patients.
1.Introduction
Henoch-Sch¨ onlein purpura (HSP) is the most common
vasculitis in children with an incidence of approximately 10
per 100,000 children per year and is slightly common among
boys (60%) than girls (40%) [1]. The diagnosis is based
on the palpable purpura in the presence of one of either
diﬀuse abdominal pain, a biopsy showing predominant
immunoglobulin A (IgA) deposition, arthritis, or arthralgia
and/or renal involvement (hematuria and/or proteinuria)
[2]. Typically, patient is a young child presenting with
clinical manifestations including palpable purpura, arthritis,
abdominal pain and gastrointestinal bleeding. The etiology
of HSP is mainly unknown and antecedent upper respira-
tory tract infection, usually viral, has been reported and
Streptococcalinfectionhasbeenemphasizedasanimportant
triggering factor [3]. Also it is known that IgA plays an
important role in the pathogenesis of the disease [1]. Most
cases are self-limiting and require no treatment apart from
symptomatic relief, but recurrence of symptoms occurs in
about 33% of the cases. It seems that relapse often occurs
between two weeks and 18 months after initial resolution of
symptoms and children with kidney involvement are more
likely to have recurrences [4]. In some patients, nephritis
occurs due to IgA deposition in the renal mesangium [1].
More serious complications such as the involvement of
central nervous system, renal failure, and intussusception
may also occur. There is no consensus on the optimal
treatment in the case of signiﬁcant renal or other organs
involvement where treatment may have a signiﬁcant impact
on the long-term outcome.
The routine use of corticosteroids in HSP is contro-
versial. In a randomized placebo controlled study of oral
prednisolone, abdominal symptoms were more prolonged in
theprednisolonegroup.Further,therewasnosigniﬁcantdif-
ference in the development of gastrointestinal complications
the exception was the development of two intussusceptions
in the placebo group and none in the steroid group [5].2 International Journal of Rheumatology
On the contrary, some retrospective studies and case reports
have suggested a beneﬁt of steroids such as prednisolone in
the treatment of abdominal pain [6, 7], HSP nephritis, and
as prophylaxis for nephropathy [8, 9]. Then, the treatment
of HSP nephritis remains controversial [4]. HSP nephritis
accounts for 1.8–3% of children with chronic kidney disease
[10] and the presence of nephrotic/nephritic syndrome has
been associated with a poor prognosis [4]. Long-term renal
impairment occurs in 19.5% of those with a history of
nephritic or nephrotic syndrome [11] which may imply a
necessity for a more aggressive treatment to improve the
outcome.
Mycophenolate mofetil (MMF), an immunosuppressive
agent, has been widely used in the organ transplantation
including pediatric renal transplantation [12]. MMF also
appears to be a promising therapeutic agent in many
autoimmune diseases such as lupus nephritis and in IgA
nephropathy which is a form of primary glomerulonephritis
[13]. Hitherto, the available evidence to support the use of
MMF in HSP is limited to some case study reports [14].
In this case series study, we report the beneﬁt eﬀect of
MMF in the treatment of some complicated HSP cases. The
study subjects include six patients admitted into pediatric
nephrology ward in a public hospital in Urmia-Iran. The
patients were admitted with the diagnosis of HSP from
March 2007 through March 2008. All the patients had been
administrated steroid initially to control their complications
including severe abdominal pain, gastrointestinal bleeding,
and severe nephritis. Subsequently, medication changed to
MMF regarding the following criteria (1) unresponsive to
steroid, (2) steroid side eﬀects, and (3) steroid dependency
(two times of relapse during steroid tapering).
2.CaseSeries
2.1. Case Number 1: A 6-year-old boy referred to our
hospital with the exacerbation of HSP symptoms including
typical diﬀuse palpable purpuric and hemorrhagic lesions,
abdominal pain, and arthritis. The patient had moon
face, body weight gain, relapse of gastrointestinal bleeding,
and severe abdominal pain despite taking prednisolone
for eight weeks (2mg/kg/day for the ﬁrst four weeks and
2mg/kg/every other day for the last four weeks). Abdominal
sonography was normal. Antistreptolysin-O (ASO) titer was
250 Todd, C reactive protein (CRP) was qualitatively positive
(+2), erythrocyte sedimentation rate (ESR) was 55mm/h,
and Antineutrophil cytoplasmic antibody (ANCA) as well
as antinuclear antibodies (ANAs) yielded negative results.
We tapered oﬀ the prednisolone gradually and switched to
MMF 30mg/kg/day. The gastrointestinal bleeding stopped
during the ﬁrst 48 hours of treatment and all symptoms and
cutaneous manifestations resolved during the ﬁrst week. The
treatment continued for the next three weeks. There was no
evidence of relapse in a 6-month follow-up.
2.2. Case Number 2: A 21-month-old boy presented with
typical diﬀuse palpable purpuric and hemorrhagic lesions,
hematuria, gastrointestinal bleeding, abdominal pain, and
Table 1: Demographic features of patients.
AGE Sex Presenting signs and
symptoms
Case 1 6 yr Male
Palpable purpura,
Hemorrhagic purpura,
Arthritis, Abdominal pain
Case 2 21 month Male
Palpable purpura,
Hemorrhagic purpura,
Arthralgia, Abdominal
pain, Hematuria,
Gastrointestinal bleeding
Case 3 2 yr Male
Palpable purpura,
Hemorrhagic purpura,
Elbow and ankle arthritis,
Abdominal pain,
Hematuria,
Gastrointestinal bleeding
Case 4 6 yr Male
Palpable purpura,
Gastrointestinal bleeding,
Abdominal pain, Arthralgia
Case 5 7 yr Female
Proteinuria, Hematuria,
Palpable purpura,
Hemorrhagic purpura,
Arthritis, Abdominal pain,
Gastrointestinal bleeding,
Generalized edema
Case 6 18 month Male
Diﬀuse purpuric lesions,
Gastrointestinal bleeding,
Severe abdominal pain,
Microscopic hematuria
arthralgia. Abdominal CT scan and sonography were nor-
mal. ASO titer was 166 Todd, CRP was +1, and ESR
was 61mm/h. Despite treatment with prednisolone for two
months (2mg/kg/day for the ﬁrst month and 2mg/kg/every
other day for the second month), there was no lasting
improvementinHSPsymptoms(abdominalpain,arthralgia,
purpuric and hemorrhagic lesions). Gastrointestinal bleed-
ing was exacerbated and two episodes of relapse observed.
He had moon face and body weight gain. Steroid therapy
changed to MMF 30mg/kg/day. Abdominal pain and gas-
trointestinal bleeding resolved in one week. Treatment with
MMFwascontinuedforthenexttwoweeksandthentapered
oﬀ in the next month. There was no evidence of relapse in a
6-month follow-up.
2.3. Case Number 3: A 2-year-old boy presented with typical
diﬀuse palpable purpuric and hemorrhagic lesions, ankle
andelbowarthritis,hematuria,gastrointestinalbleeding,and
abdominal pain. Abnormal laboratory tests were CRP =
+3, ESR = 42mm/h. Abdominal sonography and other
laboratory tests were normal. The patient was under steroid
therapy for eight weeks (2mg/kg/day) and he had moon face
and body weight gain. With tapering steroid, exacerbation
and recurrence occurred for three times (steroid depen-
dency). MMF 30mg/kg/day was administered and tapering
of steroid commenced and discontinued after three weeks.
All the clinical manifestations resolved in one month ofInternational Journal of Rheumatology 3
Table 2: Laboratory data and ultrasonographic ﬁndings of patients. ∗Only qualitative measurement of CRP was available at our center.
WBC/
mm3
Hemoglobin
gr/dL
Platelet/
mm3 CRP∗ ESR1st
hr PT/PTT ANCA
ASO (normal
< 125 U)
Todd unit
BUN
mg/dL
Creatinine
mg/dL Urinalysis Abdominal
ultrasonography
Case 1 8500 12.1 253000 ++ 55 Normal Neg. 250 12 0.6 Normal Normal
Case 2 7600 11.6 374000 + 61 Normal Neg. 166 10 0.5 Many RBC Normal
Case3 10500 11.8 320000 +++ 42 Normal Neg. Neg. 11 0.7 Many RBC Normal
Case4 9400 12.2 288000 + 29 Normal Neg. 333 14 0.5 Normal Normal
Case 5 11700 12.4 425000 +++ 74 Normal Neg. Neg. 12 0.6
Protein:
++++
Many RBC
Normal
Case 6 7800 11.6 301000 Neg. 18 Normal Neg. Neg. 13 0.5 Normal Normal
the treatment and MMF was tapered during the next month.
There was no evidence of relapse over one-year follow-up.
2.4. Case Number 4: A6 - y e a r - o l db o yw a sr e f e r r e dt oo u r
hospital with HSP symptoms exacerbation. The patient had
palpable purpura, gastrointestinal bleeding, abdominal pain,
and arthralgia in spite of taking prednisolone (2mg/kg/day)
for weeks. Abnormal laboratory tests were ASO = 333
Todd, CRP = +1, ESR = 29mm/h. Abdominal sonography
and other laboratory tests were normal. We administered
MMF 30mg/kg/day while tapering steroid therapy gradually.
Treatment with MMF continued for one month and tapered
oﬀ within the next month. There was no evidence of
recurrence over one-year follow-up.
2.5. Case Number 5: A 7-year-old girl referred to our hos-
pital due to developing nephrotic level of proteinuria (above
2gr/day)andmicroscopichematuriafollowingsteroidtaper-
ing. Before admission to our hospital, the patient had
diﬀuse palpable purpuric and hemorrhagic lesions, arthritis,
generalize edema, microscopic hematuria, gastrointestinal
bleeding, and severe abdominal pain. At the beginning of the
disease, Methylprednisolone pulse (20mg/kg/day) had been
started intravenously for three times (every other day) and
continued with oral prednisolone 2mg/kg/day for the ﬁrst
month and 2mg/kg/every other day for the second month.
Abnormal laboratory ﬁndings were CRP = +3, ESR =
74mm/hs e eT a b l e2. Other laboratory tests including serum
lipids,serumalbumin,ASO,ANCA,ANA,C3,C4,BUN,and
Scr were normal. Due to continuing signiﬁcant proteinuria
(above 2gr/day) and microscopic hematuria, renal biopsy
was performed and showed diﬀuse mesangial cell prolifer-
ation (light microscope) and predominant deposition of IgA
in mesangial matrix and basement membrane of glomerulus
(immunoﬂuorescence microscope). After admission of the
patient to our hospital, treatment with MMF 30mg/kg/day
commenced and the oral prednisolone (2mg/kg/every other
day) which had been started since 2 months ago was
discontinued.
After treatment with MMF for two months, proteinuria
diminished from 2gr/day to 130mg/day, but microscopic
hematuria continued. After six months, MMF was discon-
tinued and after a six-month follow-up there was not any
clinical and laboratory abnormality except mild microscopic
hematuria.
2.6. Case Number 6: An 18-month-old boy referred to us
due to steroid dependency and frequent recurrences while
taping steroid. The patient presented with diﬀuse purpuric
lesions, gastrointestinal bleeding, severe abdominal pain,
and microscopic hematuria in spite of taking prednisolone
(2mg/kg/day for four weeks and 2mg/kg/every other day
for six weeks). The patient was readmitted again to hospital
with gastrointestinal bleeding and arthritis for fourth times.
Abdominal sonography and laboratory tests including ESR,
CRP, and ASO were normal. After admission of the patient
to our hospital, MMF 30mg/kg/day commenced and steroid
was tapered oﬀ gradually. All clinical manifestations resolved
within one week and hematuria improved after one month
of the treatment with MMF. Treatment with MMF was
tapered oﬀ during the next month. There was no evidence
of recurrence over one-year follow-up.
3. Discussion
MMFgainsincreasingpopularityinthetreatmentofautoim-
mune disorders such as lupus nephritis, vasculitis, necro-
tizing glomerulonephritis, corticosteroid resistant glomeru-
lonephritis, and IgA nephropathy [12, 13, 15]. It has been
shown that MMF suppresses lymphocyte proliferation and
decreases antibody production in the kidney diseases [13].
Recent studies suggest that mycophenolatic acid (MPA),
the active metabolite of MMF, can signiﬁcantly inhibit the
adhesion of leukocytes to endothelial cells, which is a key
process in the development of ANCA-associated vasculitis
[16]. Hu et al. found that MMF was eﬀective in controlling
disease activity and improving renal function in Chinese
patients with MPO-ANCA-associated vasculitis [16]. In
another report, a patient with adult crescentic progressive
glomerulonephritis in whom long-term complete remission
was achieved after MMF therapy was discussed by Dede
[13]. A case of HSP that manifested after pantoprazole
ingestionhasbeenreportedrecentlybyMuzaﬀar[17].Inthis
patient, the clinical manifestations including terminal ileitis
and rapidly progressive glomerulonephritis were initially
unresponsive to intravenous pulse steroids, whereas, his4 International Journal of Rheumatology
Table 3: Treatment protocols and outcomes of patients.
Corticostroid
Dose/Route/Duration
Response to
corticostroid
Mycophenolate
mofetil (MMF)
Dose/Duration
Response to
Mycophenolate
mofetil (MMF)
Mean arterial
pressure (mmHg)
before treatment
by Mycophenolate
mofetil (MMF)
Mean arterial
pressure (mmHg)
one week after
treatment by
Mycophenolate
mofetil (MMF)
Case 1 Prednisolone 2mg/kg/d
PO for 8 weeks
Stroid
dependency
30mg/kg For 3
weeks
Signiﬁcant
recovery in 48
hours
84 86
Case 2 Prednisolone 2mg/kg/d
PO for 8 weeks
Stroid
dependency
30mg/kg For 6
weeks
Signiﬁcant
recovery in one
week
78 77
Case 3 Prednisolone 2mg/kg/d
PO for 8 weeks
Stroid
dependency
30mg/kg For 8
weeks
Signiﬁcant
recovery in one
month
80 80
Case 4 Prednisolone 2mg/kg/d
PO for 2 weeks No response 30mg/kg For 8
weeks
Signiﬁcant
recovery in one
month
86 85
Case 5
Methyl prednisolone
20mg/kg IV for 3 doses
every other day then
Prednisolone 2mg/kg/d
for ﬁrst 4 weeks and
2mg/kg/everyotherday
for second 4weeks
No response 30mg/kg For 6
month
Signiﬁcant
recovery of
proteinuria but
continuation of
microscopic
hematuria
86 90
Case 6
Prednisolone 2mg/kg/d
PO for ﬁrst 4 weeks and
2mg/kg/everyotherday
for second 4weeks
Stroid
dependency
30mg/kg For 8
weeks
Signiﬁcant
recovery in one
month
76 79
renal function recovered after treatment with MMF [17].
In a study, the clinical courses of six patients (four boys
and two girls with mean age of 13.2 years) with HSP and
nephrotic syndrome were reviewed [18]. In this study, the
treatment protocols included oral prednisolone, and in the
nonresponders included cyclosporine A, cyclophosphamide,
MMF, or tacrolimus see Table 3. They suggested that
an early aggressive immunosuppressive approach improves
long-term renal outcome in HSP patients with nephrotic
syndrome [18].
Filler et al. described the pharmacokinetics of MMF in
15 pediatric patients with vasculitis and connective tissue
diseasesinvolvingthekidney.Therapywaseﬀectiveininduc-
ing remission in four of nine patients with active diseases.
Relapse occurred in only one of ﬁve other patients. All of six
patients withcontrolleddisease maintained remission. There
were few side eﬀects including diarrhea and leukocytopenia
in one case and viral infections in two cases. They conclude
that MMF at 900mg/m2 per day appears to be eﬀective in
these patients [19].
In our case series study, we report six cases with HSP
in whom steroid therapy failed to treat complications and
keepinpersistentremissionso,medicationswitchedtoMMF
(Table 1). All patients were closely followed up at least for
six months for any complaint, symptoms, and signs of HSP
such as palpable purpura, and arthritis. Blood pressure,
serum creatinine level, complete blood count, platelet count,
hematocrit, urine analysis, urine protein measurement, and
side eﬀects of MMF have been checked in the patients.
In our study, MMF was found to be a useful immuno-
suppressant due to its fewer undesirable eﬀects and good
treatment eﬀects for control of complication and relapse of
HSP.
There was not any signiﬁcant side eﬀect, except mild
anemia in the case 2 (not required any intervention) and
mild diarrhea in the case 3 which relived by changing
MFMtofourdivideddoses.HSPmanifestationsdisappeared
mainly during the ﬁrst week of treatment with MMF. With
the exception of one patient with persistent hematuria for a
long time, all the patients achieved complete remission at the
end and after discontinuation of the therapy.
In our experience, MMF appeared to be eﬀective for
maintenance of remission in HSP patients.
There is some evidence to support steroid therapy in the
treatment of severe abdominal pain, gastrointestinal bleed-
ing,severenephritis,andcentralnervoussysteminvolvement
[20]. However, as seen in our patients, frequent relapses,
lack of response to steroid, steroid dependency, and steroid
side eﬀects have been reported [14, 15]. In literature the
other treatment choices in complicated and sever HSP
patients varied from combined heavy immunosuppressant
(Cyclosporine, Cyclophosphmide) therapy to plasmaphere-
sis [21]. So, we considered a more speciﬁc alternative to
steroid therapy for HSP patients.International Journal of Rheumatology 5
On the other hand, considering favorable experiences
with MMF such as less adverse eﬀects than other immuno-
suppressive drugs, beneﬁt eﬀects in the treatment of many
immunologically mediated renal diseases, and the antiﬁ-
broticandantiproliferativeeﬀectsofit[22,23],itissuggested
that MMF can be especially valuable in the treatment of the
complicated HSP.
According to this case series study, MMF can be a
safe and eﬀective medication in the treatment of the
complicated HSP. So, therapy could be changed to MMF
considering the following criteria: unresponsive to steroid,
steroid side eﬀects, and steroid dependency (two relapses
during steroid tapering). However, there are some important
factors that may inﬂuence the results of our study including
the possibility of spontaneous improvement of HSP without
intervention, therapeutic eﬀects of antecedent steroid before
starting MMF. It is important to point out that we do not
claimMMFworksinallpatientsandsomepatientswithHSP
may fail MMF and may require more aggressive treatment.
So, more controlled prospective studies are necessary to
prove the eﬃcacy of this medication in the HSP treatment.
4. Conclusion
The results of this case series study suggest that mycopheno-
late mofetil would be a promising therapeutic alternative in
the treatment of the complicated HSP. However, multicentre
clinical trials with long-term followup will be necessary
to conﬁrm eﬀectiveness of MMF in the treatment of the
complicated HSP patients.
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